Skip to content
  • All
  • Liver
  • NASH
  • NASH-HCC
  • Obesity
  • 3D Imaging
  • Others
Screenshot 2024-07-04 122859
Protected: Understanding c-Fos and Its Applications in CNS Research

This is a password protected post.

Breakthroughs in Innovative Peptide Therapeutics

Therapeutic peptides have gained increasing interest in drug discovery. Compared to small molecule therapeutics, peptide-based drugs often show more selective receptor binding and thus present with less off-target related adverse…

selecting preclinical CRO
Important Checklist for Selecting the Right Preclinical CRO: 32 Questions to Ask

It is essential to choose the right preclinical contract research organization (CRO) that understands your research needs and provides you with quality results. Getting conclusive preclinical results with clear data…

cfos purple
Anti-obesity drug development: Industry trends in 2024

With over 750 million individuals worldwide classified as obese, according to the World Health Organization, the urgency to combat this global health crisis has reached unprecedented levels. Obesity is associated…

CDAA-HFD rat
FDA approved Madrigal’s Resmetirom (Rezdiffra®) as first drug treatment for MASH. What now?

As a major landmark in drug development for metabolic dysfunction-associated steatohepatitis (MASH; previously known as NASH, nonalcoholic steatohepatitis), the Food and Drug Administration (FDA) recently approved Resmetirom (Rezdiffra®, Madrigal Pharmaceuticals)…

top-ranked MASH model
GAN DIO-MASH model is top-ranked by the LITMUS consortium

Gubra’s GAN DIO-MASH mouse model has been top-ranked by the LITMUS¹ consortium for its human proximity score. The LITMUS consortium has evaluated a wide variety of preclinical MASH models using two key…

Subscribe for

Company updates

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top